Sphera Funds Management LTD. Purchases 151,661 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sphera Funds Management LTD. lifted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 108.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,080 shares of the company’s stock after buying an additional 151,661 shares during the period. Sphera Funds Management LTD. owned about 0.29% of Intellia Therapeutics worth $5,982,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in NTLA. Blue Trust Inc. boosted its stake in Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank acquired a new position in Intellia Therapeutics in the 3rd quarter worth $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics in the 3rd quarter worth $54,000. Finally, First Horizon Advisors Inc. boosted its stake in Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the period. Institutional investors own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. reduced their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Citigroup reduced their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Canaccord Genuity Group restated a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $14.49 on Thursday. Intellia Therapeutics, Inc. has a twelve month low of $12.82 and a twelve month high of $34.87. The company’s 50-day moving average price is $16.88 and its two-hundred day moving average price is $21.14.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm’s revenue was down 24.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.38) earnings per share. On average, analysts forecast that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.